FABP4 and Hepatic steatosis: Additionally, the dual peroxisome proliferator-activated receptor α/δ (PPAR α/δ) agonist GFT505 (elafibranor), which has shown a potential therapeutic effect against NASH in clinical trials, reduced the liver FABP4 expression and ameliorated hepatic steatosis, inflammation, and fibrosis in a choline-deficient, L-amino acid-defined high-fat diet-induced MASH model [143].